Human colorectal cancers are known to possess multiple mutations, though how these mutations interact in tumor development and progression has not been fully investigated. We have previously described the FCPIK3ca* murine colon cancer model, which expresses a constitutively activated phosphoinositide-3 kinase (PI3K) in the intestinal epithelium. The expression of this dominantly active form of PI3K results in hyperplasia and invasive mucinous adenocarcinomas. These cancers form via a non-canonical mechanism of tumor initiation that is mediated through activation of PI3K and not through aberrations in WNT signaling. Since the Adenomatous Polyposis Coli (APC) gene is mutated in the majority of human colon cancers and often occurs simultaneously with PIK3CA mutations, we sought to better understand the interaction between APC and PIK3CA mutations in the mammalian intestine. In this study, we have generated mice in which the expression of a constitutively active PI3K and the loss of APC occur simultaneously in the distal small intestine and colon. Here, we demonstrate that expression of a dominant active PI3K synergizes with loss of APC activity resulting in a dramatic change in tumor multiplicity, size, morphology and invasiveness. Activation of the PI3K pathway is not able to directly activate WNT signaling through the nuclear localization of CTNNB1 (b-catenin) in the absence of aberrant WNT signaling. Alterations at the transcriptional level, including increased CCND1, may be the etiology of synergy between these activated pathways.
INTRODUCTION
Colorectal adenocarcinoma continues to be a major etiology of morbidity and mortality despite significant advances in the understanding of tumor biology and treatment options. 1 The profile of mutations has now been characterized in multiple human cancers; however, the role of these mutations in tumorigenesis, progression and response to therapy has largely yet to be defined. 2 Adenomatous Polyposis Coli (APC) mutations have been well characterized as important mediators of colorectal tumorigenesis. 3 Germline mutations were discovered in patients with familial adenomatous polyposis, but somatic mutations are also present in 80-90% of sporadic colorectal polyps and cancers. 4 These mutations lead to truncation of the APC protein resulting in the loss of function of this tumor suppressor. Loss of APC function results in dysregulation of CTNNB1 (b-catenin), leading to increased WNT pathway signaling through MYC and CCND1 (cyclin D1), among others. 5 The Apc Min/ þ (Min) mouse carries a germline mutation in Apc, which results in these mice developing many adenomas throughout the intestinal tract. 6 This model has been widely used to study the biology of intestinal tumors and as a valuable tool for chemoprevention studies.
Genetic alterations in the phosphoinositide-3 kinase (PI3K) signaling pathway are the most common mutations found in cancer. 7 Oncogenic mutations of PIK3CA are important in multiple cancer types, including 20-30% of colorectal cancers. 8 Mutations of the PIK3CA gene encode for a dominant active form of the p110a catalytic subunit of PI3K and occur in three hotspots: E454K, E456K and H1047R. 9 PIK3CA mutations have been investigated in numerous cancer cell lines; however, until recently the effect of a dominant active PI3K in the mammalian intestine had not been investigated. Our laboratory has developed a murine model, FCPIK3ca*, that expresses a dominant active form of PI3K (p110*) in the distal small bowel and colon. 10 This model develops sessile large moderately differentiated invasive mucinous adenocarcinomas in the proximal colon through a non-canonical mechanism and without a polypoid luminal component.
APC and PIK3CA mutations are commonly identified together in human colorectal cancers, yet the interaction between these mutations remains to be investigated in the mammalian intestine. 11 The potential for cross-talk between these signaling cascades has been an area of interest. These pathways converge on glycogen synthase kinase 3 (GSK3) and potentially other mediators. Prior studies in cell culture models have had contradictory findings when examining the potential for an interaction between these signaling cascades. [12] [13] [14] [15] [16] [17] To examine what effect mutations in APC and PIK3CA have on tumorigenesis, we have crossed the Min mouse with the FCPIK3ca* ( Min/ þ mice become moribund by 52 days of age on average due to obstructive enteropathy or anemia. At necropsy, large proximal colon cancers result in distention of the cecum and small intestine (a) compared with control (b). These tumors are associated with enlarged mesenteric adenopathy (c). In addition, an impressive vascular supply is noted supplying tumors in the colon (c) and distal small intestine (d). The colon was removed and split lengthwise demonstrating a large flat proximal colon cancer and other smaller tumors in the colon (e). The distal small intestine was also resected and split lengthwise revealing multiple large tumors (f). The mesentery was also examined closely following removal of the colon and small intestine. Hyperplasia of the lymphatic tissue was seen in all mice (c, g). In some mice, tumor deposits were seen in the mesenteric adipose tissue (g, h) or within the lymphatic tissue (g, i). Size bars: (g) ¼ 2 mm; (h, i) ¼ 1 mm. (h, i) Enlargements of the boxes in (g).
dominant active PI3K (3K 1 ) in the distal small intestine and colon due to the expression of Cre under the control of the fatty acid binding protein-1 promoter (FC  1 ) . Here, we demonstrate increased tumor multiplicity, size and a more aggressive and poorly differentiated phenotype as a consequence of synergy between APC and PIK3CA mutations.
RESULTS
Expression of a dominantly active PI3K in the setting of allelic loss of Apc results in increased tumor multiplicity and increased tumor size FC 1 3K
1 Apc Min/ þ mice were dissected once moribund with agematched control littermates (Figure 1; 1 denotes carrier and 0 denotes non-carrier for FC and 3K; þ denotes wild type for Apc). The majority of mice developed massive proximal colon cancers resulting in obstruction of the lumen (Figure 1a ). These tumors were associated with an impressive vascular supply and hyperplastic lymphatic tissue (Figures 1c and d) . Tumors are seen in the colon and distal small intestine (Figures 1e and f) . In some instances, metastatic lesions were noted in the mesenteric lymphatic and adipose tissue (Figures 1g-i Table S1 ). The average age of FC 1 3K
1 Apc Min/ þ mice at necropsy was 52 days old. Mice appeared well until they became moribund from obstructive enteropathy relating to large obstructing colon cancers or secondary to anemia from bleeding intestinal tumors.
Tumor multiplicity was significantly increased in each section of the intestine where the activated PI3K was expressed in the setting of allelic loss of Apc (Figure 2) . Overall, an average of 8.7 tumors were identified throughout the intestine in 
Apc
Min/ þ mice. No increase in tumor multiplicity was noted in the proximal most intestinal sections, segments 1 and 2, which lack activated PI3K. This is useful as an internal control and indicates that the increase in tumor multiplicity is related to expression of constitutively active PI3K.
The intestinal sections from FC 1 3K 1 Apc Min/ þ mice and associated controls were also evaluated for tumor size. Fixed tissues were examined under the dissecting microscope. The maximum diameter of each tumor was determined using a measuring reticule. The flat FC 1
3K
1 proximal colon tumors, as previously described, 10 were not measured as these tumors do not have discrete borders, which are required for reproducible measurements.
An increase in tumor size was noted in segment 4 and the colon (Figure 2b) (Figures 2-4 10 S1-S2 S3-S4 Cecum-colon Figure 2 . Activation of the PI3K pathway in the intestine results in increased tumor number and size. In the FC 1 3K 1 Apc Min/ þ , the median number of tumors seen was 8.7 compared with the control littermates which averaged 2.2 or less (a). This effect was seen prominently in the colon, where the FC 1
1 Apc Min/ þ mice have a mean of 2.9 tumors per mouse and only 1 colon tumor was seen in 32 Apc
Min/ þ control littermates (a). In the proximal small intestine, no difference was noted in tumor number which is consistent with the activated form of PI3K not being expressed in this area in the 1 Apc Min/ þ mice develop multiple tumors with distinct morphologies. Large flat moderately differentiated mucinous adenocarcinomas develop in the proximal colon (a, d). This cancer penetrates through the serosal surface consistent with a T4 lesion. Polypoid intramucosal carcinomas arising in the setting of villous/serrated hyperplasia are seen also in the proximal colon (b, e). In the mid and distal colon, tumors range from small adenomas to large adenomas with high-grade dysplasia to adenocarcinomas. A large adenoma with solid growth pattern and a focal area of adenocarcinoma in the submucosa is pictured in (c, f ). The flat mucinous lesions do not possess nuclear CTNNB1 (g), while the polypoid tumors demonstrate nuclear CTNNB1 IHC staining (h, i). The MKI67 and phospho-AKT IHC staining of all of these tumors indicates that these tumors are highly proliferative and have activated PI3K/AKT signaling (j-o). Scale bars: (d) ¼ 1 mm; (e) ¼ 500 mm; (f ) ¼ 1 mm. All experiments were completed at least in triplicate.
seen in the small intestine of FC 1 3K 1 Apc Min/ þ mice, whereas only a limited number of small adenomas were seen in control littermates. The lesions of both the small and large intestine exhibited uptake of a novel near-infrared phospholipid ether analog, CLR1502, that selectively accumulates in advanced tumors (Supplementary Figure S4) . 
Apc
Min/ þ mice largely did not demonstrate nuclear CTNNB1 staining ( Figure 5; Supplementary Figures S3  and S5) . However, the polypoid lesions of the colon did demonstrate a high degree of nuclear CTNNB1. Microscopic adenomas are even able to be identified in the colon due to their high degree of nuclear CTNNB1 staining (Supplementary Figure S5) .
These data indicate that tumors in the FC 1 3K 1 Apc Min/ þ mice are developing via different mechanisms. In the flat proximal invasive colon adenocarcinomas, the lack of nuclear CTNNB1 indicates that these tumors are not initiated by aberrant WNT signaling. Their non-canonical mechanism of tumorigenesis needs to be further clarified. In the polypoid colonic lesions, where CTNNB1 is nuclear, these tumors are likely initiated by loss of APC and their more aggressive phenotype driven by the presence of the dominantly active PI3K. Interestingly, in two flat mucinous proximal colon cancers, thought to be initiated by PI3K, small foci of nuclear CTNNB1 were identified ( Figure 5 ). The morphology of the cells in these regions also changed. This indicates that the cells with nuclear CTNNB1 likely lost the other allele of Apc after tumor initiation by activated PI3K. The change in morphology indicates that important phenotypic changes in the tumor might occur even if APC is lost after tumor initiation and not just as the initiator of tumorigenesis. Figure S6) . 19 The microsatellite allelic patterns of 18 out of 22 tumor samples and matching normal samples were identical and therefore were considered as microsatellite stable. Four tumors contained a novel allele at the mBat-66 locus that was not present in wild-type C57BL/6 mice. However, this novel allele was the same in all four tumors and is, therefore, likely due to a polymorphism in these F1 mice. Thus, MSI does not appear to have a role in intestinal tumorigenesis in . This indicates that the polypoid lesions are arising secondary to aberrant WNT signaling, while the flat mucinous lesions form via a non-canonical mechanism. Rarely, the large flat mucinous adenocarcinomas have islands of cells with nuclear CTNNB1 (e, H&E; f, CTNNB1). The cells with nuclear CTNNB1 also have a different morphology (g, h, enlargements of e and f, respectively), with a higher nucleus-to-cytoplasm ratio, nuclear enlargement and hyperchromasia, and a more basophilic cytoplasm. Scale bars: (a, b) ¼ 1 mm; (e, f ) ¼ 1 mm; (c, d, g, h) ¼ 100 mm.
Similar tumor multiplicity and phenotypes are seen when Apc is lost only in the epithelial cells of the intestine in the setting of a constitutively active PI3K In the Min mouse, one allele of Apc is lost in all cells. Prior investigations have indicated that the loss of APC in stromal tissue may be important for tumorigenesis. 20 To investigate this further, we used a transgenic mouse with a Cre recombinase conditional knockout of Apc (Apc fl/ þ ). 21 This mouse contains an allele of Apc that is floxed at exon 14. In the presence of Cre, exon 14 is removed and the APC protein is truncated. These mice were used to generate genetically homogenous FC 
Min/ þ mice, they also developed advanced small intestine and colon cancers ( Figure 6) (Figure 7a) .
The PI3K and WNT signaling pathways are known to converge on GSK3; however, the role of GSK3 in cross-talk between these two pathways remains controversial. In the majority of flat 
Min/ þ cancers nuclear localization of CTNNB1 was not observed (Figures 3 and 5 ).
In addition, no change in total CTNNB1 was observed between the majority of FC 
DISCUSSION
Human colorectal cancers are a heterogeneous group, with each cancer individualized by its mutation profile. The presence of certain mutations may change with the biological context, such as the possible interaction between PIK3CA mutations and bowel inflammation. This is important clinically as patients with this mutation are more likely to benefit from adjuvant aspirin therapy. 22 In addition, certain mutations are often associated with each other. Of colon tumors with PIK3CA mutations, 86% of these cancers also possess mutant APC.
11 In addition, PIK3CA mutations have also been associated with KRAS and BRAF mutations, CpG island methylator phenotype and MSI. [23] [24] [25] Concerted efforts to develop improved and more personalized treatment options for all types of cancer continue. Recent advances include improved targeting of directed therapies against the mutational activation of signaling pathways in cancer. This has led to the development of classes of exciting anti-neoplastic agents, such as EGFR, BRAF, MEK, EML4-ALK, MET, MTOR and PI3K inhibitors. To properly develop and utilize these new therapies, a better understanding of how the mutation profile of each cancer affects the tumor biology is required. It is important to recognize the roles of these mutant proteins and how their function is altered by the presence of mutations in other oncogenes or tumor suppressors. Here, we report the first in vivo description of the interaction between APC and PIK3CA mutations in mammalian intestinal tumors.
Previously, we have demonstrated that a dominant active PI3K is able to initiate the development of flat mucinous invasive adenocarcinomas in the proximal colon via a non-canonical mechanism of tumorigenesis. 10 In addition to these lesions, we now demonstrate that the presence of a dominant active PI3K in the setting of allelic loss of APC results in increased tumor multiplicity, size, and a more aggressive and less differentiated phenotype. We have demonstrated that this is related to increased activation of AKT and phosphorylation of downstream targets including RPS6 and EIF4EBP1.
Interestingly, in the flat proximal colonic mucinous invasive adenocarcinomas, these tumors carry germline mutations in one allele of Apc. However, in two tumors we observed the loss of APC activity as a likely later event. In this setting, cells that lost APC after tumor initiation secondary to PI3K had a change in morphology to a less differentiated state. This indicates that, in addition to tumor initiation, the loss of APC can be a late event in tumorigenesis, and could be responsible for clonal outgrowth in some instances, such as was observed here.
The mechanism for the synergy between WNT and PI3K signaling pathways may occur due to a direct interaction between these pathways. Previous studies have aimed to examine this interaction; however, they have been contradictory. GSK3 is well known to have an important role in both WNT and PI3K signaling, and thus has been a target of multiple investigations examining these pathways. GSK3 is a serine-threonine kinase that occurs in two isoforms GSK3A and GSK3B. 26 These kinases are naturally constitutively active and are inhibited by N-terminal phosphorylation of Ser-21 for GSK3A and Ser-9 for GSK3B, which results in the formation of a pseudosubstrate motif. 27 In WNT signaling, GSK3 has an important role in the degradation of CTNNB1. GSK3 is bound by Axis inhibition protein (AXIN1) and phosphorylates CTNNB1. 28 This phosphorylation of CTNNB1 targets it for ubiquitination and degradation by proteosomes. If GSK3 is inhibited by WNT signaling, then this leads to CTNNB1 accumulation and nuclear translocation, though the mechanism of WNT inhibition of GSK3 remains poorly understood. In PI3K signaling, phosphorylated AKT in turn phosphorylates GSK3 on its inhibitory serines. 29 Multiple studies have demonstrated that an interaction between these pathways might exist related to a single pool of GSK3. [12] [13] [14] [15] Contrary to these findings, other groups have proposed that cross-talk between these two pathways does not exist. 16, 17 Ng et al. 17 demonstrated that a pool of GSK3B is stably bound to AXIN1 and represents only about 3-5% of the total GSK3B. They also observed that the phosphorylation level of the AXIN1-bound GSK3B was independent of PI3K pathway activation by insulin or inhibition by wortmannin.
Some evidence indicates that the context in which phospho-AKT signaling is taking place has an effect on its ability to inhibit GSK3B that is bound to AXIN1 and thus acting in WNT signaling. Fukumoto et al. 13 demonstrated that phospho-AKT is bound to the AXIN1:GSK3B complex in the presence of Dishevelled, promoting phosphorylation of GSK3B and accumulation of free CTNNB1. However, if the WNT cascade was not activated by Dishevelled, then phospho-AKT was not found to be bound to the AXIN1:GSK3B complex and free CTNNB1 levels were not elevated. These data indicate that phospho-AKT is not sufficient, but can enhance the activity of WNT signaling. These findings are consistent with those of Ng and colleagues as WNT was not activated in their experiments.
Here, we demonstrate synergy between the loss of the tumor suppressor APC and the presence of a dominant active PI3K.
Min/ þ mice demonstrate increased tumor multiplicity, size and aggressiveness compared with the tumors of control littermates. In the flat mucinous adenocarcinomas, an increase in pGSK3B is observed; however, this is without change in the total levels or nuclear localization of CTNNB1. This proves that phospho-AKT is insufficient for activation of the WNT signaling pathway in this context. In the polypoid tumors, variable phosphorylation of GSK3B was seen. Again, no change in total CTNNB1 levels was seen, but significant nuclear localization of CTNNB1 was noted similar to that seen in Apc Min/ þ controls. We cannot exclude the possibility that phospho-AKT signaling is able to enhance CTNNB1 signaling in the presence of an aberrant WNT pathway, such as mutant Apc. Significant levels of nuclear MYC were seen in all the tumors assayed and CCND1 was increased in the FC 1 3K 1 Apc Min/ þ tumors above the level seen in Apc Min/ þ tumors, indicating a potential etiology for the synergy between these mutations at the transcriptional level. In summary, synergy exists between the loss of the tumor suppressor APC and the presence of a dominant active PI3K in this in vivo model of colon cancer. Further studies are required to elucidate to what extent cross-talk between these pathways exists and is responsible for this synergy. In addition, pharmacologic studies using this and similar models will be vital to the development of novel combination therapies for the personalized treatment of patients with colorectal and other cancers. Tumors from Apc Min/ þ and (SWRxB6) F1 Apc Min/ þ mice treated with 4% dextran sodium sulfate were used as controls.
MATERIALS AND METHODS

Tumor fixation and counts
Mice were euthanized by CO 2 asphyxiation. At necropsy, the entire intestine was excised. The small intestine was divided into four sections of equal length (numbered 1 through 4 from proximal to distal) and the colon and cecum were kept intact. Each section of the intestine was then split lengthwise, splayed open, and rinsed. Tissues were fixed flat in 10% buffered formalin for 24-48 h, then stored in 70% ethanol. Tumors in each section of the intestine were counted under a dissecting microscope by a single observer who was blinded to the genotypes.
Histology and immunohistochemistry
Fixed tumors were isolated, embedded in paraffin, and cut into 5 mm sections. Every tenth section was stained with hematoxylin and eosin for histological review. IHC was carried out as described previously. 10 The primary antibodies included rabbit anti-phospho-AKT (Ser473, 1:100, Cell Signaling Technology, Beverly, MA, USA), mouse anti-CTNNB1 (1:200, BD Biosciences-Clone 14, San Diego, CA, USA), rabbit anti-PCNA (Ki-67) (1:1000, Cell Signaling Technology), and CCND1 (1:25, Cell Signaling Technology). The IHC protocol was modified for the anti-MYC antibody N-262 (1:50, Santa Cruz Biotechnology, Dallas, TX, USA) as follows. Upon rehydration, slides were incubated in 0.05% sodium borohydride (SigmaAldrich, St Louis, MO, USA) for 10 min followed by incubation in 0.5% Triton X-100 (Sigma-Aldrich). Slides were blocked for 20 min at room temperature with a fresh blocking solution (2.5 ml 1 M Tris-HCl pH 8.0, 2 ml 5 M NaCl, 2 ml 10% NP-40, 5 g non-fat dry milk, distilled deionized water to 100 ml).
Western blot analysis
Tissue was processed and gels run as previously described. 10 The gels were probed with primary antibodies against p110a, phospho-AKT (Ser473), RPS6 (Ser235/236), phosphor-EIF4EBP1 (Thr37/46), pMAPK (Thr202/Tyr 204), pGSK3A, pGSK3B or Total GSK3 (Cell Signaling Technology) in bovine serum albumin (Sigma-Aldrich) at a 1:1000 ratio for 16 h. Anti-CTNNB1 (BD Biosciences-Clone 14) was probed at a ratio of 1:5000. Anti-GAPDH antibody (Cell Signaling Technology) was utilized as a loading control at a ratio of 1:5000. 
MSI analysis
Apc
Min/ þ mice were tested for MSI using a multiplex of six mononucleotide repeat loci designed specifically for MSI testing of C57BL/6 mice, including: mBat-56 (GTGTGTATGCTGATTTTATATCCT, GCAAAAATATCATTCGGTATG), mBat-57 (TGAAATCCTTGATGTTCCTCTACTAGGT, GGTCATCCTGTTGTTTCTAAATGAT . PCR products were denatured in deionized formamide with Internal Lane Standard 600 (Promega) for allele sizing and analyzed on a 3130xl Genetic Analyzer using GeneMapper 4.0 Software (Applied Biosystems). For MSI analysis, the microsatellite allelic patterns of tumor and matching normal samples were compared and classified as microsatellite stable if no loci were unstable, MSI-Low if one locus was unstable, and MSI-High if two or more loci were unstable. 32 
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